Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil.
Experimental Medicine Research Cluster (EMRC), University of Campinas, Campinas, SP, Brazil.
Adv Exp Med Biol. 2021;1286:251-264. doi: 10.1007/978-3-030-55035-6_17.
Psychiatric and neurodegenerative disorders such as schizophrenia (SCZ), Parkinson's disease (PD), and Alzheimer's disease (AD) continue to grow around the world with a high impact on health, social, and economic outcomes for the patient and society. Despite efforts, the etiology and pathophysiology of these disorders remain unclear. Omics technologies have contributed to the understanding of the molecular mechanisms that underlie these complex disorders and have suggested novel potential targets for treatment and diagnostics. Here, we have highlighted the unique and common pathways shared between SCZ, PD, and AD and highlight the main proteomic findings over the last 5 years using in vitro models, postmortem brain samples, and cerebrospinal fluid (CSF) or blood of patients. These studies have identified possible therapeutic targets and disease biomarkers. Further studies including target validation, the use of large sample sizes, and the integration of omics findings with bioinformatics tools are required to provide a better comprehension of pharmacological targets.
精神神经疾病，如精神分裂症（SCZ）、帕金森病（PD）和阿尔茨海默病（AD），在全球范围内不断增多，对患者和社会的健康、社会和经济结果产生重大影响。尽管付出了努力，但这些疾病的病因和发病机制仍不清楚。组学技术有助于理解这些复杂疾病的分子机制，并为治疗和诊断提供了新的潜在靶点。在这里，我们强调了 SCZ、PD 和 AD 之间独特和共同的途径，并强调了过去 5 年来使用体外模型、尸检脑组织样本以及患者的脑脊液（CSF）或血液进行的主要蛋白质组学发现。这些研究已经确定了可能的治疗靶点和疾病生物标志物。需要进一步的研究，包括目标验证、使用大样本量以及将组学发现与生物信息学工具相结合，以提供对药理靶点的更好理解。
